JP2008534546A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534546A5
JP2008534546A5 JP2008503447A JP2008503447A JP2008534546A5 JP 2008534546 A5 JP2008534546 A5 JP 2008534546A5 JP 2008503447 A JP2008503447 A JP 2008503447A JP 2008503447 A JP2008503447 A JP 2008503447A JP 2008534546 A5 JP2008534546 A5 JP 2008534546A5
Authority
JP
Japan
Prior art keywords
component
kit according
prostate
administered
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008503447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534546A (ja
JP5635231B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/003194 external-priority patent/WO2006103112A2/en
Publication of JP2008534546A publication Critical patent/JP2008534546A/ja
Publication of JP2008534546A5 publication Critical patent/JP2008534546A5/ja
Application granted granted Critical
Publication of JP5635231B2 publication Critical patent/JP5635231B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008503447A 2005-03-31 2006-03-31 活性物質の局所送達に基づく前立腺疾患の治療方法 Expired - Fee Related JP5635231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500452 2005-03-31
DKPA200500452 2005-03-31
PCT/EP2006/003194 WO2006103112A2 (en) 2005-03-31 2006-03-31 Method for treating prostate diseases based on local delivery of active substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012258603A Division JP2013067639A (ja) 2005-03-31 2012-11-27 活性物質の局所送達に基づく前立腺疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2008534546A JP2008534546A (ja) 2008-08-28
JP2008534546A5 true JP2008534546A5 (cg-RX-API-DMAC7.html) 2009-05-21
JP5635231B2 JP5635231B2 (ja) 2014-12-03

Family

ID=35044589

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008503447A Expired - Fee Related JP5635231B2 (ja) 2005-03-31 2006-03-31 活性物質の局所送達に基づく前立腺疾患の治療方法
JP2012258603A Ceased JP2013067639A (ja) 2005-03-31 2012-11-27 活性物質の局所送達に基づく前立腺疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012258603A Ceased JP2013067639A (ja) 2005-03-31 2012-11-27 活性物質の局所送達に基づく前立腺疾患の治療方法

Country Status (17)

Country Link
US (1) US8936809B2 (cg-RX-API-DMAC7.html)
EP (1) EP1865924B1 (cg-RX-API-DMAC7.html)
JP (2) JP5635231B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140014294A (cg-RX-API-DMAC7.html)
CN (1) CN101160116B (cg-RX-API-DMAC7.html)
AU (1) AU2006228675B2 (cg-RX-API-DMAC7.html)
CA (1) CA2602776C (cg-RX-API-DMAC7.html)
DK (1) DK1865924T3 (cg-RX-API-DMAC7.html)
ES (1) ES2557988T3 (cg-RX-API-DMAC7.html)
HU (1) HUE026158T2 (cg-RX-API-DMAC7.html)
IL (1) IL185690A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007011908A (cg-RX-API-DMAC7.html)
NO (1) NO338679B1 (cg-RX-API-DMAC7.html)
PL (1) PL1865924T3 (cg-RX-API-DMAC7.html)
RU (1) RU2404747C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006103112A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708066B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
MX2011005243A (es) * 2008-11-27 2011-08-08 Lidds Ab Uso de carboximetilcelulosa para controlar la eyectabilidad y el tiempo de solidificacion de las composiciones que comprenden una o mas ceramicas biorreabsorbibles.
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016028774A1 (en) 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2020061291A1 (en) * 2018-09-20 2020-03-26 Biovena Science, Llc Flutamide microsphere-based arterial embolization for treating prostate disorders
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en) * 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
EP4469108A1 (en) * 2022-01-29 2024-12-04 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US5795330A (en) 1996-10-10 1998-08-18 Etex Corporation Mixing device
CA2268156C (en) * 1996-10-16 2007-05-29 Etex Corporation Bioceramic compositions
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5972384A (en) * 1997-10-01 1999-10-26 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
CA2378486A1 (en) 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
US8404681B2 (en) * 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
GB0307082D0 (en) * 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
JP4927535B2 (ja) * 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
PL1680089T3 (pl) * 2003-10-22 2014-03-31 Lidds Ab Kompozycja zawierająca biodegradowalną ceramikę hydratującą do kontrolowanego dostarczania leków
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법

Similar Documents

Publication Publication Date Title
JP2007518805A5 (cg-RX-API-DMAC7.html)
NZ580226A (en) Dimer compounds as inhibitors of iap
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
PE20061122A1 (es) Composiciones que incluyen hierro
RU2012111235A (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
UA95955C2 (ru) Ингибиторы обратной транскриптазы вич
JP2007523049A5 (cg-RX-API-DMAC7.html)
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
JP2010507593A5 (cg-RX-API-DMAC7.html)
RU2004126950A (ru) Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний
EP2147927A3 (en) Use of 131i-tm-601 for the diagnosis and treatment of gliomas
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
JP2009506054A5 (cg-RX-API-DMAC7.html)
EA200600524A1 (ru) Способы лечения эндометриоза
JP2006502236A5 (cg-RX-API-DMAC7.html)
WO2007084560A8 (en) INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
EP1749830A4 (en) CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS
ATE505488T1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
PT1583538E (pt) Utilização da 3-metoxi-pregnenolona para a preparação de um medicamento destinado a tratar as doenças neurodegenerativas
JP2012512157A5 (cg-RX-API-DMAC7.html)
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors